Article Text

Download PDFPDF

113 A single-cell spatially resolved atlas of immune-mediated control of lung adenocarcinoma
  1. Tito Panciera1,
  2. Francesca Zanconato1,
  3. Michelangelo Cordenonsi1,
  4. Mattia Forcato2,
  5. Giada Vanni1,
  6. Silvio Bicciato2,
  7. Julian Preciado3,
  8. Saskia Ilcisin3,
  9. Katrina Raay3,
  10. Margaret Hoang3,
  11. Michael Patrick3,
  12. Shanshan He4,
  13. Joseph Beechem3 and
  14. Stefano Piccolo1
  1. 1University of Padua School of Medicine, Padua, Padua, Italy
  2. 2University of Modena and Reggio Emilia, Modena, Modena, Italy
  3. 3NanoString Technologies, Inc., Seattle, WA, USA
  4. 4NanoString Technologies, Inc., Redmond, WA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Despite the ever-expanding weaponry of molecularly targeted and immunotherapy approaches, lung adenocarcinoma continues to stand as the leading cause of cancer-related mortality. One of the most frequently occurring mutations in lung cancer is KRAS mutations. For many years, these mutations were considered untargetable. However, the recent development of chemical inhibitors that specifically target oncogenic variants of Ras, particularly the commonly mutated KRAS-G12D isoform, represents a significant breakthrough in targeted therapeutics. An appealing aspect of KRas mutation targeted drugs is their ability to alert the immune system and enhance its ability to attack cancer cells. Nevertheless, the tissue-level mechanisms underlying the cell-autonomous and non-cell-autonomous effects of KRas-G12D inhibitors are poorly understood. Additionally, the effectiveness of KRas-G12D inhibitors in lung cancer models remains unknown. To address these gaps in knowledge, we aimed to investigate tumor regression and the body’s ability to combat established tumors. Specifically, we analyzed the spatial interactions between cancer cells and the surrounding tissue microenvironment during the process of tumor eradication mediated through KRas-G12D inhibitors.

Methods We utilized a genetic mouse model of non-small cell lung cancer (NSCLC), driven by the activation of KRas-G12D in combination with the loss of p53. We investigated the immune-mediated tumor recognition following the targeting of KRas-G12D in an immunocompetent setting. scRNA-seq and spatial transcriptomic analysis (CosMxTM Spatial Molecular Imager 1,000-plex Mouse Universal Cell Characterization Panel) were employed to obtain a high-plex, single-cell, temporal and spatially resolved molecular atlas of lung tumor regression. This approach enabled the multimodal profiling, systematic exploration and reconstruction of cellular neighborhoods.

Results Through the analysis of cell-to-cell interactions within spatial neighborhoods, we demonstrate the tremendous potential of the molecular histology of NSCLC. This powerful approach allows us to simultaneously characterize various features, including cell types, molecular states, and receptor-ligand interactions, within niche-specific signaling networks that play a crucial role in the immune attack and eventual eradication of tumors.

Conclusions This study provides novel insights into the temporal and spatial dynamics of KRas-G12D inhibitor-mediated tumor regression in lung cancer, shedding light on the previously unknown cell-cell interactions occurring during this process. By investigating these spatiotemporal aspects, we aim to enhance our understanding of lung cancer biology and potentially identify new immunotherapeutic biomarkers. Moreover, the research tools used in this study have implications for the design of future preclinical studies exploring the potential of immuno-oncology combination therapies.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.